262 related articles for article (PubMed ID: 26831328)
1. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
Brade KD; Rybak JM; Rybak MJ
Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
[TBL] [Abstract][Full Text] [Related]
2. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Das B; Sarkar C; Schachter J
Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
[TBL] [Abstract][Full Text] [Related]
3. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
4. Oritavancin for acute bacterial skin and skin structure infections.
Messina JA; Fowler VG; Corey GR
Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
[TBL] [Abstract][Full Text] [Related]
5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
6. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
[TBL] [Abstract][Full Text] [Related]
7. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
8. Oritavancin: an investigational lipoglycopeptide antibiotic.
Karaoui LR; El-Lababidi R; Chahine EB
Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
[TBL] [Abstract][Full Text] [Related]
9. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.
Mitra S; Saeed U; Havlichek DH; Stein GE
Infect Drug Resist; 2015; 8():189-97. PubMed ID: 26185459
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.
Kmeid J; Kanafani ZA
Core Evid; 2015; 10():39-47. PubMed ID: 25709561
[TBL] [Abstract][Full Text] [Related]
12. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
Bouza E; Burillo A
Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
[TBL] [Abstract][Full Text] [Related]
13. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
14. Oritavancin: A Novel Lipoglycopeptide.
Mattox J; Belliveau P; Durand C
Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
[TBL] [Abstract][Full Text] [Related]
15. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
Stewart CL; Turner MS; Frens JJ; Snider CB; Smith JR
Infect Dis Ther; 2017 Jun; 6(2):277-289. PubMed ID: 28386776
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
[TBL] [Abstract][Full Text] [Related]
17. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.
Johnson JA; Feeney ER; Kubiak DW; Corey GR
Open Forum Infect Dis; 2015 Dec; 2(4):ofv156. PubMed ID: 26677455
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
19. Oritavancin: A Long-Half-Life Lipoglycopeptide.
Saravolatz LD; Stein GE
Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
[TBL] [Abstract][Full Text] [Related]
20. Oritavancin: a long-acting antibacterial lipoglycopeptide.
Kaasch AJ; Seifert H
Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]